Drug Search Results
More Filters [+]

Buprenorphine

Alternative Names: buprenorphine, probuphine, subutex, butrans, cam-2038, cam2038, cam 2038, Sublocade, sixmo, buprenorphin, belbuca, buprenex, norspan, suboxone, zubsolv, bunavail, cassipa
Latest Update: 2024-09-10
Latest Update Note: News Article

Product Description

Buprenorphine, a partial mu-opoid receptor agonist, has unique pharmacologic properties that distinguish it from methadone and other medications used in the treatment of opioid dependence. It has been shown to be as effective as methadone and is generally safe and well-tolerated. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994593/)

Mechanisms of Action: OPRM Agonist,OPRD Antagonist,OPRK Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Sublingual,Transdermal,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Pain Unspecified | Substance Abuse Unspecified | Opioid-Related Disorders | Pain Unspecified | Substance Abuse Unspecified | Opioid-Related Disorders | Opioid-Related Disorders

Known Adverse Events: Dizziness | Headache | Erythema | Pruritus | Constipation | Depressive Disorder | Back Pain | Pain Unspecified | Toothache | Hyperhidrosis | Edema | Insomnia

Company: Indivior
Company Location: SLOUGH X0 SL13UH
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Buprenorphine

Countries in Clinic: Australia, Egypt, United States, Unknown Location

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Neonatal Abstinence Syndrome|Opioid-Related Disorders|Pregnancy Outcomes|Substance Withdrawal Syndrome

Phase 2: Low Back Pain|Radiculopathy|Sciatica

Phase 1: Pain, Postoperative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ED-ENVISION

P3

Not yet recruiting

Opioid-Related Disorders

2027-02-01

NIDA-CTN-0100

P2

Recruiting

Opioid-Related Disorders

2026-07-01

EXHITENTRE

P3

Recruiting

Opioid-Related Disorders

2026-01-01

MOMs-INO

P3

Recruiting

Opioid-Related Disorders|Neonatal Abstinence Syndrome|Substance Withdrawal Syndrome|Pregnancy Outcomes

2025-01-31

Recent News Events